Document is current

Article History

Received: 16 January 2024

Accepted: 25 January 2024

First Online: 29 February 2024

Declarations

:

: YH obtained speaker fee from Sumitomo Pharma. DY obtained grants from Novo Nordisk, Terumo, Taisho, Arklay and Boehringer Ingelheim. DY also obtained consulting or speaker fees from Boehringer Ingelheim, Novo Nordisk, Sumitomo Pharma, Kyowa Kirin, Eli Lilly and Sanofi.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients for being included in the study. The study protocol was approved by the Institutional Review Board of Gifu University (No. 29–191). Written informed consent was obtained from all participants.